# Immunogenicity, Reactogenicity of Shingrix in SLE

> **NCT06001606** · PHASE3 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 63 (estimated)

## Conditions studied

- Zoster
- Systemic Lupus Erythematosus
- Vaccine Reaction

## Interventions

- **DRUG:** Shingrix
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06001606
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-08
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-04-24
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001606, "Immunogenicity, Reactogenicity of Shingrix in SLE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06001606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*